La Jolla Pharmaceutical Co banner
L

La Jolla Pharmaceutical Co
F:LJPP

Watchlist Manager
La Jolla Pharmaceutical Co
F:LJPP
Watchlist
Price: 6.072 EUR Market Closed
Market Cap: €151.2m

La Jolla Pharmaceutical Co
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

La Jolla Pharmaceutical Co
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
L
La Jolla Pharmaceutical Co
F:LJPP
Goodwill
$20.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Goodwill
$35.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
2%
Exact Sciences Corp
NASDAQ:EXAS
Goodwill
$2.4B
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.1B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
36%
No Stocks Found

La Jolla Pharmaceutical Co
Glance View

Market Cap
151.2m EUR
Industry
Biotechnology

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.

LJPP Intrinsic Value
Not Available
L

See Also

What is La Jolla Pharmaceutical Co's Goodwill?
Goodwill
20.1m USD

Based on the financial report for Jun 30, 2022, La Jolla Pharmaceutical Co's Goodwill amounts to 20.1m USD.

What is La Jolla Pharmaceutical Co's Goodwill growth rate?
Goodwill CAGR 1Y
0%

Over the last year, the Goodwill growth was 0%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett